financetom
Business
financetom
/
Business
/
Looking At Intuit's Recent Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Looking At Intuit's Recent Unusual Options Activity
Mar 25, 2024 2:13 PM

Benzinga's options scanner just detected over 16 options trades for Intuit (NASDAQ:INTU) summing a total amount of $1,132,096.

At the same time, our algo caught 9 for a total amount of 1,125,462.

Expected Price Movements

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $600.0 and $900.0 for Intuit, spanning the last three months.

Volume & Open Interest Development

In today's trading context, the average open interest for options of Intuit stands at 196.33, with a total volume reaching 1,775.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Intuit, situated within the strike price corridor from $600.0 to $900.0, throughout the last 30 days.

Intuit Option Volume And Open Interest Over Last 30 Days

Significant Options Trades Detected:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
INTU PUT SWEEP BEARISH 06/21/24 $610.00 $227.2K 57 122
INTU PUT SWEEP BULLISH 06/21/24 $600.00 $201.1K 1.0K 328
INTU PUT SWEEP BULLISH 06/21/24 $600.00 $185.1K 1.0K 450
INTU PUT SWEEP BULLISH 06/21/24 $600.00 $164.7K 1.0K 106
INTU PUT SWEEP BULLISH 06/21/24 $600.00 $123.5K 1.0K 450

About Intuit

Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.

Present Market Standing of Intuit

With a volume of 966,212, the price of INTU is down -0.72% at $639.09.

RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.

Next earnings are expected to be released in 57 days.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Intuit, Benzinga Pro gives you real-time options trades alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sagimet Biosciences Names Thierry Chauche CFO
Sagimet Biosciences Names Thierry Chauche CFO
May 6, 2024
09:12 AM EDT, 05/06/2024 (MT Newswires) -- Sagimet Biosciences ( SGMT ) said Monday that it has appointed Thierry Chauche as its chief financial officer, effective the same day. Chauche was most recently the CFO of Provention Bio, Sagimet said. Shares of the company were up 2.6% in recent Monday premarket activity. Price: 4.4300, Change: +0.11, Percent Change: +2.55 ...
Synopsys to Sell Software Integrity to Clearlake, Francisco Partners
Synopsys to Sell Software Integrity to Clearlake, Francisco Partners
May 6, 2024
09:10 AM EDT, 05/06/2024 (MT Newswires) -- Synopsys ( SNPS ) said Monday it has agreed to sell its Software Integrity Group business to Clearlake Capital Group and Francisco Partners in a deal with a total value of up to $2.1 billion, including up to $475 million in cash payable upon Francisco Partners and Clearlake achieving a specified rate of...
GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink
GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink
May 6, 2024
On Monday, GlycoMimetics Inc. ( GLYC ) announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute myeloid leukemia (R/R AML).  In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone. Patients treated with uproleselan had a median overall survival of 13 months, compared to 12.3 months in the...
TELUS Unveiling GenAI Customer Support Tool Powered by Fuel iX and Microsoft Azure OpenAI Service
TELUS Unveiling GenAI Customer Support Tool Powered by Fuel iX and Microsoft Azure OpenAI Service
May 6, 2024
09:12 AM EDT, 05/06/2024 (MT Newswires) -- TELUS ( TU ) (T.TO, TU) on Monday unveiled a new generative AI (GenAI)-powered customer support tool for TELUS.com, that is powered by Fuel iX and Microsoft OpenAI Service. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved